Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 4.8%

Adaptimmune Therapeutics plc (NASDAQ:ADAP) shares fell 4.8% during mid-day trading on Tuesday . The company traded as low as $1.00 and last traded at $1.00. 507,917 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,785,425 shares. The stock had previously closed at $1.05.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Adaptimmune Therapeutics in a research report on Friday, December 29th. They issued a “hold” rating for the company.

Adaptimmune Therapeutics Trading Down 2.9 %

The stock’s 50-day moving average is $1.42 and its 200-day moving average is $0.91. The stock has a market cap of $1.01 billion, a P/E ratio of -1.82 and a beta of 2.39.

Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.12). Adaptimmune Therapeutics had a negative net margin of 188.90% and a negative return on equity of 155.39%. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $4.80 million. On average, equities analysts forecast that Adaptimmune Therapeutics plc will post -0.44 EPS for the current year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Large investors have recently made changes to their positions in the business. Bank of America Corp DE lifted its stake in Adaptimmune Therapeutics by 357.8% during the fourth quarter. Bank of America Corp DE now owns 4,738,612 shares of the biotechnology company’s stock valued at $6,918,000 after buying an additional 3,703,418 shares in the last quarter. Baillie Gifford & Co. lifted its position in shares of Adaptimmune Therapeutics by 17.1% in the fourth quarter. Baillie Gifford & Co. now owns 17,169,939 shares of the biotechnology company’s stock worth $25,068,000 after purchasing an additional 2,505,003 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Adaptimmune Therapeutics by 724.5% in the second quarter. Renaissance Technologies LLC now owns 1,506,375 shares of the biotechnology company’s stock worth $1,393,000 after purchasing an additional 1,323,675 shares in the last quarter. Citigroup Inc. lifted its position in shares of Adaptimmune Therapeutics by 35,078.0% in the second quarter. Citigroup Inc. now owns 582,196 shares of the biotechnology company’s stock worth $539,000 after purchasing an additional 580,541 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Adaptimmune Therapeutics in the fourth quarter worth approximately $403,000. Institutional investors own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.